(Q40165924)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326159%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326159%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326159%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Martin R. Sprick

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326159%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Wolfgang Stremmel

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326159%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Ronald Koschny

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326159%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Tom M Ganten

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326159%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Jaromir Sykora

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326159%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Armin Kolb

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326159%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Henning Walczak

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326159%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

language of work or name

English

0 references

publication date

1 March 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326159%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326159%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326159%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

649-658

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326159%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326159%20AND%20SRC:MED&resulttype=core&format=json

Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells

26 December 2019

cites work

1 reference

Identification and characterization of a new member of the TNF family that induces apoptosis

21 January 2018

1 reference

7 January 2021

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

7 January 2021

Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.

1 reference

7 January 2021

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

1 reference

7 January 2021

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

1 reference

7 January 2021

TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice

1 reference

7 January 2021

The clinical trail of TRAIL.

1 reference

7 January 2021

Apoptosis: a relevant tool for anticancer therapy

1 reference

7 January 2021

Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy

1 reference

7 January 2021

Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.

1 reference

7 January 2021

Bortezomib treatment for multiple myeloma

1 reference

7 January 2021

Role of BAX in the apoptotic response to anticancer agents

1 reference

7 January 2021

Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.

1 reference

7 January 2021

BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis

1 reference

7 January 2021

Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector

1 reference

7 January 2021

Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases.

1 reference

7 January 2021

Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer

1 reference

7 January 2021

Approval summary for bortezomib for injection in the treatment of multiple myeloma

1 reference

7 January 2021

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

1 reference

7 January 2021

The proteasome: a suitable antineoplastic target

1 reference

7 January 2021

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21555

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17326159%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference